P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP

P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP

Bibliographic Details
Main Authors:	Qiu-Sha Huang, Hai-Xia Fu, Chen-Cong Wang, Xiao-Lu Zhu, Yun He, Qi Chen, Jin Wu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000973288.67955.a3

Similar Items

Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
by: Lucie Čermáková, et al.
Published: (2022-09-01)

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
by: Liang Wang, et al.
Published: (2021-04-01)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
by: Heather Zhang, et al.
Published: (2021-12-01)

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
by: Amneh Fares, et al.
Published: (2024-02-01)

Second-generation inhibitors of Bruton tyrosine kinase
by: Jingjing Wu, et al.
Published: (2016-09-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Abdullah Mohammad Khan
Published: (2022-04-01)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
by: Rhodes JM, et al.
Published: (2021-03-01)

P1197: BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN RELAPSED/REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF CENTRAL NERVOUS SYSTEM: A PHASE II TRIAL
by: Yali Wang, et al.
Published: (2023-08-01)

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
by: Laura Airas, et al.
Published: (2024-04-01)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
by: Zhou-Peng Xiao, et al.
Published: (2023-03-01)

Expression of Bruton's tyrosine kinase in osteoclasts
by: Danks, L, et al.
Published: (2005)

Editorial: Targeting Bruton Tyrosine Kinase
by: Cornelia Brunner, et al.
Published: (2022-04-01)

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
by: Yuqin Song, et al.
Published: (2023-10-01)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
by: Alexander N. R. Weber, et al.
Published: (2017-11-01)

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
by: Philipp von Hundelshausen, et al.
Published: (2021-03-01)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
by: Piyu Parth Naik
Published: (2022-01-01)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
by: Max J. Gordon, et al.
Published: (2021-01-01)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
by: Max Von Suskil, et al.
Published: (2021-05-01)

Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.
by: Hong Ma, et al.
Published: (2013-01-01)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
by: Xianhui Wang, et al.
Published: (2021-07-01)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
by: Skye Montoya, et al.
Published: (2023-07-01)

Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
by: Haoran Wang, et al.
Published: (2022-09-01)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
by: Yuko Ariza, et al.
Published: (2019-06-01)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
by: Kun Wang, et al.
Published: (2021-01-01)

Role of Bruton’s tyrosine kinase in B cells and malignancies
by: Simar Pal Singh, et al.
Published: (2018-02-01)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
by: Stefan F. H. Neys, et al.
Published: (2021-06-01)

Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective
by: Yekta Ghane, et al.
Published: (2023-12-01)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
by: Chakrapani Balijepalli, et al.
Published: (2023-08-01)

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
by: Simei Qiu, et al.
Published: (2021-08-01)

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
by: Jin Wang, et al.
Published: (2017-07-01)

498 Bruton’s tyrosine kinase (BTK) inhibitors impede platelet aggregation but not adhesion to collagen.
by: Thomas Kartika, et al.
Published: (2024-04-01)

Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies
by: Mohammed Alrouji, et al.
Published: (2023-10-01)

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
by: Hyewon Cho, et al.
Published: (2020-10-01)

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
by: Dariusz Rozkiewicz, et al.
Published: (2023-03-01)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
by: Mitra Rezaei, MD, et al.
Published: (2022-01-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
by: Danling Gu, et al.
Published: (2021-03-01)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
by: Brooke Benner, et al.
Published: (2021-01-01)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
by: Zemene Demelash Kifle
Published: (2021-09-01)